(EMAILWIRE.COM, March 27, 2017 ) Epilepsy is characterized by recurrent seizures caused by the improper balance between inhibitory and excitatory signals in the brain. The symptoms of epilepsy, caused by brain malformations and tumors, birth trauma, and high-risk pregnancies, can be benign or life-threatening. A majority of epilepsy cases have an unknown etiology.
Etiology
Etiology varies according to the age of a person. Some individuals genetically inherit the disease while the cause of the disease in others is unknown. Head injuries, tumors, autism spectrum disorder, or stroke can also cause the disorder.

Publisher's analysts forecast the global epilepsy drugs market to grow at a CAGR of 4.45% during the period 2016-2020.
For more information about this report: http://www.reportsweb.com/global-epilepsy-drugs-market-2016-2020 .
Covered in this report
The report covers the present scenario and the growth prospects of the global epilepsy drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic drugs used to treat and prevent epilepsy and related seizures. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of marketed drugs during the forecast period.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

Publisher's report, Global Epilepsy Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Eisai
- GSK
- Pfizer
- UCB

Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001309791/sample .

Other prominent vendors
- AbbVie
- Acorda Therapeutics
- Alexza Pharmaceuticals
- Aprecia Pharmaceuticals
- Aurobindo Pharma
- Biscayne Pharmaceuticals
- CURx Pharmaceuticals
- Dainippon Sumitomo Pharma
- D-Pharm
- F. Hoffmann-La Roche
- Grupo Ferrer Internacional
- GW Pharmaceuticals
- Insero Health
- INSYS Therapeutics
- Janssen Pharmaceuticals
- Ligand Pharmaceuticals
- H. Lundbeck
- MarcoPolo Pharmaceuticals
- Marinus Pharmaceuticals
- Meda
- Neurelis
- Nobelpharma
- Novartis
- Orphelia Pharma
- SAGE Therapeutics
- SciFlour
- Sedor Pharmaceuticals
- Shire
- SK Biopharmaceuticals
- Sun Pharmaceutical
- Sunovion Pharmaceuticals (US)
- Supernus Pharmaceuticals
- Takeda
- Turing Pharmaceuticals
- Upsher-Smith
- Valeant Pharmaceutical
- Zogenix

Market driver
- Tentative approval of late-stage pipeline molecules
- For a full, detailed list, view our report

Market challenge
- Social stigma associated with epilepsy
- For a full, detailed list, view our report

Market trend
- Reformulation of marketed drugs
- For a full, detailed list, view our report

Make an enquiry: http://www.reportsweb.com/inquiry&RW0001309791/buying .

Contact Information:
ReportsWeb.com
Priya Sisodia
Tel: +1-646-491-9876
Email us


----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results